Recent advances in the management of cutaneous lymphomas

The treatment options for patients with primary cutaneous B- and T-cell lymphomas are as diverse as the diseases themselves, including both skin-directed and systemic therapies. Long-term remission can be attained in many cases; however, no treatment is curative with the possible exception of allogeneic stem cell transplant. Improved insight into the molecular biology and pathophysiology of these diseases has led to the development of novel drugs and targeted therapies, including monoclonal antibodies and antimetabolites, as well as improved radiotherapeutic techniques. We aim to summarize these new and emerging treatment modalities, and to outline how they may be integrated into the clinical management of patients with primary cutaneous lymphoma (CL).